Literature DB >> 16081106

Adjunctive herbal medicine with carbamazepine for bipolar disorders: A double-blind, randomized, placebo-controlled study.

Zhang-Jin Zhang1, Wan-Hu Kang, Qing-Rong Tan, Qiang Li, Cheng-Ge Gao, Feng-Gang Zhang, Huai-Hai Wang, Xian-Cang Ma, Ce Chen, Wei Wang, Li Guo, Ya-Hong Zhang, Xiao-Bo Yang, Guang-De Yang.   

Abstract

Chinese herbal medicines possess the therapeutic potential for mood disorders. This double-blind, randomized, placebo-controlled study was designed to evaluate the efficacy and side effects of the herbal medicine called Free and Easy Wanderer Plus (FEWP) as an adjunct to carbamazepine (CBZ) in patients with bipolar disorders. One hundred and twenty-four bipolar depressed and 111 manic patients were randomized to treatment with CBZ alone, CBZ plus FEWP, or equivalent placebo for 12 weeks. CBZ was initiated at 300mg/day and FEWP was given at a fixed dose of 36g/day. Efficacy measures included the Hamilton Rating Scale for Depression, Montgomery-Asberg Depression Rating Scale , Young Mania Rating Scale, Bech-Rafaelsen Mania Scale, and Clinical Global Impression-Severity (CGI-S). CBZ monotherapy produced significantly greater improvement on manic measures at week 2 through endpoint and CGI-S of depression at endpoint compared to placebo. CBZ monotherapy also yielded significantly higher clinical response rates than placebo on bipolar depression (63.8% vs. 34.8%, p=0.044) and mania (87.8% vs. 57.1%, p=0.012). Compared to CBZ monotherapy, adjunctive FEWP with CBZ resulted in significantly better outcomes on the three measures of depression at week 4 and week 8 and significantly greater clinical response rate in depressed subjects (84.8% vs. 63.8%, p=0.032), but failed to produce significantly greater improvement on manic measures and the response rate in manic subjects. There was a lesser incidence of dizziness and fatigue in the combination therapy compared to CBZ monotherapy. These results suggest that adjunctive FEWP has additive beneficial effects in bipolar patients, particularly for those in depressive phase.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16081106     DOI: 10.1016/j.jpsychires.2005.06.002

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  13 in total

Review 1.  New findings from the Bipolar Collaborative Network: clinical implications for therapeutics.

Authors:  Robert M Post; Lori L Altshuler; Mark A Frye; Trisha Suppes; Susan McElroy; Paul E Keck; Gabriele S Leverich; Ralph Kupka; Willem A Nolen; Heinz Grunze
Journal:  Curr Psychiatry Rep       Date:  2006-12       Impact factor: 5.285

Review 2.  [Pharmaceutical treatment of bipolar depression. Evidence from clinical guidelines and treatment recommendations].

Authors:  S Köhler; M Bauer; T Bschor
Journal:  Nervenarzt       Date:  2014-09       Impact factor: 1.214

Review 3.  The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise Algorithm.

Authors:  Konstantinos N Fountoulakis; Lakshmi Yatham; Heinz Grunze; Eduard Vieta; Allan Young; Pierre Blier; Siegfried Kasper; Hans Jurgen Moeller
Journal:  Int J Neuropsychopharmacol       Date:  2017-02-01       Impact factor: 5.176

4.  [Acute and long-term treatment for bipolar depression].

Authors:  H Grunze; S Dargel
Journal:  Nervenarzt       Date:  2010-05       Impact factor: 1.214

Review 5.  Thirty years of clinical experience with carbamazepine in the treatment of bipolar illness: principles and practice.

Authors:  Robert M Post; Terence A Ketter; Thomas Uhde; James C Ballenger
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

6.  Complementary and alternative medicine use for treatment and prevention of late-life mood and cognitive disorders.

Authors:  Helen Lavretsky
Journal:  Aging health       Date:  2009-02-01

Review 7.  Efficacy of Carbamazepine and Its Derivatives in the Treatment of Bipolar Disorder.

Authors:  Anna Grunze; Benedikt L Amann; Heinz Grunze
Journal:  Medicina (Kaunas)       Date:  2021-04-30       Impact factor: 2.430

8.  Chinese herbal medicine and depression: the research evidence.

Authors:  Lee Butler; Karen Pilkington
Journal:  Evid Based Complement Alternat Med       Date:  2013-02-10       Impact factor: 2.629

9.  Management of bipolar depression.

Authors:  Jae Seung Chang; Kyooseob Ha
Journal:  Indian J Psychol Med       Date:  2011-01

Review 10.  Therapeutic approaches employing natural compounds and derivatives for treating bipolar disorder: emphasis on experimental models of the manic phase.

Authors:  Vânia Machado Recart; Luiza Spohr; Mayara Sandrielly Pereira Soares; Karina Pereira Luduvico; Francieli Moro Stefanello; Roselia Maria Spanevello
Journal:  Metab Brain Dis       Date:  2021-07-15       Impact factor: 3.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.